UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

The New England journal of medicine, 2013-08, Vol.369 (8), p.722-731

2013

Link zum Volltext

Verfügbarkeit prüfen

Case Report: Disease progression of renal cell carcinoma containing a novel putative pathogenic KAT6A::NRG1 fusion on Ipilimumab- Nivolumab immunotherapy. A case study and review of the literature

Frontiers in oncology, 2023-02, Vol.13, p.1111706

2023

Link zum Volltext

Verfügbarkeit prüfen

Management of crizotinib therapy for ALK -rearranged non-small cell lung carcinoma: An expert consensus

Lung cancer (Amsterdam, Netherlands), 2015-02, Vol.87 (2), p.89-95

2015

Link zum Volltext

Verfügbarkeit prüfen

Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?

European urology open science (Online), 2023-09, Vol.55, p.15-22

2023

Link zum Volltext

Verfügbarkeit prüfen

Axitinib in advanced renal cell carcinoma: real-life data and dose modification audit

Clinical medicine (London, England), 2019-03, Vol.19 (2), p.s54-s54

2019

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

The Lancet (British edition), 2016-04, Vol.387 (10030), p.1837-1846

2016

Link zum Volltext

Verfügbarkeit prüfen

A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer

European urology, 2016-03, Vol.69 (3), p.450-456

2016

Link zum Volltext

Verfügbarkeit prüfen

Trends in whole-brain radiotherapy and survival outcomes in the era of molecular testing in lung cancer

The Royal College of Radiologists Open, 2023-12, Vol.1, p.100039, Article 100039

2023

Link zum Volltext

Verfügbarkeit prüfen

Molecular testing in non-small cell lung cancer: a snapshot of The Royal Free London NHS Foundation Trust experience

Lung cancer (Amsterdam, Netherlands), 2021-06, Vol.156, p.S38

2021

Link zum Volltext

Verfügbarkeit prüfen

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

The lancet oncology, 2023-03, Vol.24 (3), p.213-227

2023

Link zum Volltext

Verfügbarkeit prüfen

Renal mass biopsy — a practical and clinicopathologically relevant approach to diagnosis

Nature reviews. Urology, 2024-06

2024

Link zum Volltext

Verfügbarkeit prüfen

The Outcome of Patients Treated with Sunitinib Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer

European urology, 2011-09, Vol.60 (3), p.448-454

2011

Link zum Volltext

Verfügbarkeit prüfen

Real-world safety and efficacy data of patients with synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N+I) and the primary tumour (PT) in place

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e17083-e17083

2020

Link zum Volltext

Verfügbarkeit prüfen

Impact of the first surge of the COVID‐19 pandemic on a tertiary referral centre for kidney cancer

BJU international, 2021-12, Vol.128 (6), p.752-758

2021

Link zum Volltext

Verfügbarkeit prüfen

Learning from Crisis: a Multicentre Study of Oncology Telemedicine Clinics Introduced During COVID-19

Journal of cancer education, 2022-12, Vol.37 (6), p.1861-1869

2022

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS4597-TPS4597

2021

Link zum Volltext

Verfügbarkeit prüfen

NAXIVA: A phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer (RCC) with venous invasion

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.275-275

2021

Link zum Volltext

Verfügbarkeit prüfen

Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e16578-e16578

2018

Link zum Volltext

Verfügbarkeit prüfen

The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer

Clinical cancer research, 2013-12, Vol.19 (24), p.6924-6934

2013

Link zum Volltext

Verfügbarkeit prüfen

A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS5103-TPS5103

2020

Link zum Volltext

Verfügbarkeit prüfen

Surgical Safety of Deferred Cytoreductive Nephrectomy Following Pretreatment with Immune Checkpoint Inhibitor–based Dual Combination Therapy

European urology oncology, 2022-06, Vol.5 (3), p.373-374

2022

Link zum Volltext

Verfügbarkeit prüfen

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment

European urology open science (Online), 2022-01, Vol.35, p.54-58

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(34)

Publikationsform

Sprache

Englisch
(38)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Humans
(14)
Oncology
(12)
Female
(10)
Male
(10)
Carcinoma, Renal Cell - Drug Therapy
(8)
Urology & Nephrology
(8)
Adult
(7)
Aged
(7)
Kidney Cancer
(7)
Kidney Neoplasms - Drug Therapy
(7)
Kidney Neoplasms - Pathology
(7)
Middle Aged
(7)
Treatment Outcome
(7)
Disease-Free Survival
(6)
Biological And Medical Sciences
(5)
Medical Sciences
(5)
Nephrectomy
(5)
Patients
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

Case Report: Disease progression of renal cell carcinoma containing a novel putative pathogenic KAT6A::NRG1 fusion on Ipilimumab- Nivolumab immunotherapy. A case study and review of the literature

Management of crizotinib therapy for ALK -rearranged non-small cell lung carcinoma: An expert consensus

Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer

Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?

Axitinib in advanced renal cell carcinoma: real-life data and dose modification audit

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer

Trends in whole-brain radiotherapy and survival outcomes in the era of molecular testing in lung cancer

Molecular testing in non-small cell lung cancer: a snapshot of The Royal Free London NHS Foundation Trust experience

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Renal mass biopsy — a practical and clinicopathologically relevant approach to diagnosis

A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)

Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)

The Outcome of Patients Treated with Sunitinib Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer

Real-world safety and efficacy data of patients with synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N+I) and the primary tumour (PT) in place

Impact of the first surge of the COVID‐19 pandemic on a tertiary referral centre for kidney cancer

Learning from Crisis: a Multicentre Study of Oncology Telemedicine Clinics Introduced During COVID-19

A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)

NAXIVA: A phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer (RCC) with venous invasion

Cabozantinib in metastatic renal cell carcinoma (mRCC): Real world experience from the UK

The Effect of VEGF-Targeted Therapy on Biomarker Expression in Sequential Tissue from Patients with Metastatic Clear Cell Renal Cancer

A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)

Surgical Safety of Deferred Cytoreductive Nephrectomy Following Pretreatment with Immune Checkpoint Inhibitor–based Dual Combination Therapy

Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment

Suchergebnisse filtern